Halozyme Therapeutics Insider Sold Shares Worth $6,610,501, According to a Recent SEC Filing

MT newswire2026/10/09 07:42

03:42 AM EDT, 10/09/2026 (MT Newswires) -- Helen Torley, Director, President and Chief Executive Officer, on October 06, 2026, sold 60,000 shares in Halozyme Therapeutics (HALO) for $6,610,501. Following the Form 4 filing with the SEC, Torley has control over a total of 767,780 common shares of the company, with 767,780 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000140/xslF345X05/wk-form4_1791503775.xml

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

AI drives "light" merger and acquisition: Marvell Technology (MRVL.US) seeks to acquire Lumentum (LITE.US), potentially entering the top ten largest tech deals in history

Marvell is in talks to acquire optical device maker Lumentum, which currently has a market value of 8.3 billion dollars. The transaction may be announced next week.

智通财经•2026/10/29 00:51

Australian Dollar holds above 0.7050 as hot CPI boosts RBA hike bets

FXStreet•2026/10/29 00:00

China International Capital Corporation: Fed Rate Hikes Are Not Over, But No Need to Act Hastily

格隆汇•2026/10/28 23:54

Commodity cost headwinds increase to 2.5 billions USD, Ford Motor (F.US) sees core profit edge up 4% against the trend in Q3 and raises its annual guidance lower limit

Ford's Q3 adjusted EPS exceeded expectations by 20%, and the company raised the lower end of its full-year profit guidance to $10.5 billion; however, revenue slightly missed expectations, causing shares to fall nearly 2% after hours.

智通财经•2026/10/28 23:26